[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dual-antiplatelet-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dual-antiplatelet-therapy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,40,70,126,154,179,194,223],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100476995","phase-4-comparison-of-reduced-dapt-followed-by-p2y12-inhibitor-monotherapy-with-prasugrel-vs-standard-regimen-in-stemi-patients-100476995",false,"NCT05491200","Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients","COMPARE STEMI ONE- Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients Treated With OCT-guided vs aNgio-guided completE Revascularization","Inclusion Criteria:\n\nEligibility at index procedure\n\nAll STEMI patients who are planned to be treated with PCI:\n\nST segment elevation myocardial infarction\n\nChest discomfort suggestive of cardiac ischemia ≥20 min at rest with 1 of the following ECG features:\n\n* ST segment elevation ≥2 contiguous ECG leads\n* new or presumably new left bundle branch block\n\nIn patients with multivessel disease, treatment only of the culprit lesion \u002F target vessel during primary PCI is recommended.\n\nEligibility at 30-45 days\n\n* All patients who have provided informed consent\n* Compliance to DAPT with no regimen modifications (Non-adherence Academic Research Consortium 0)\n* No occurrence of significant event (such as MI, unplanned revascularisation, stent thrombosis, stroke, major vascular complication\u002Fbleeding BARC Types 3 or greater).\n* Successful revascularization: - Successful delivery and deployment of the Study device(s), with final residual stenosis of \\\u003C30% (visually) for all target lesions.\n* Complete revascularization performed when more than 1 significant lesion, during the index procedure or in staged procedure(s) occurring within 15 days from the index procedure. Physiologic assessment highly recommended for lesions with stenosis between 50% and 90%.\n\nExclusion criteria\n\n* Patients on oral anticoagulation\n* Contraindication to P2Y12 inhibitors and\u002For to Cardioaspirin or to any of the excipients (hypersensitivity, history of any stroke or transient ischemic attack within the last 12 months, active bleeding or haemorrhagic diathesis, fibrin-specific fibrinolytic therapy less than 24 h before randomization, severe hepatic dysfunction (Child-Pugh C), history of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines, history of gastrointestinal perforation or acute gastrointestinal ulcers, severe cardiac failure (NYHA grade III or IV), combination with methotrexate at doses of 15 mg\u002Fweek or more).\n* Patients who have received P2Y12 inhibitors other than Prasugrel in the ambulance (Ticagrelor or Clopidogrel loading dose) or are already on P2Y12 inhibitors, may be enrolled in the protocol, provided that the Prasugrel loading dose is administered at admission, according to current guidelines recommendations (see section 5.2.2).\n* Concomitant oral or i.v. therapy with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice \\>1L\u002Fday), CYP3A substrates with narrow therapeutic indices (e.g., cyclosporine, quinidine), or strong CYP3A inducers (e.g., rifampin), - rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital\n* Platelet count \\\u003C100.000\u002FμL at the time of screening\n* Anemia (hemoglobin \\\u003C10 g\u002FdL) at the time of screening\n* Comorbidities associated with life expectancy \\\u003C1 year\n* Pregnancy, giving birth within the last 90 days, or lactation (see appendix III for women of childbearing potential)\n* PCI indication for stent thrombosis or previous history of definite stent thrombosis\n* Non-deferrable major surgery on DAPT after PCI\n* Cardiogenic shock\n* Out of hospital cardiac arrest (OHCA) unless survivors of ventricular arrythmia with prompt return of spontaneous circulation (ROSC)\n* Patients with severe renal impairment: creatinine clearance ≤30 ml\u002Fmin\u002F1.73 m2 (as calculated by MDRD formula for estimated GFR).\n* Patients participating in another interventional (device of drug trial) within the previous 12 months or patients to whom an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer.\n* No informed consent","ALL",{"count":18,"type":19},1656,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and efficacy endpoints.\n\nIn the subgroup of STEMI patients with MVD, a sub-randomization will allow a comparison between a complete revascularization OCT-guided versus complete revascularization angiography-guided stent in terms of efficacy and safety endpoints.",[25,26],"ST Elevated Myocardial Infarction","Dual Antiplatelet Therapy","RECRUITING","2026-06-30",{"date":30,"type":31},"2026-07-02","ACTUAL",{"date":33,"type":31},"2022-07-22",{"date":35,"type":19},"2029-08-01",{"name":37,"class":38},"Research Maatschap Cardiologen Rotterdam Zuid","OTHER",27,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100591512","ticagrelor-based-dual-antiplatelet-therapy-duration-in-cabg-100591512","NCT06981390","Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG","Ticagrelor-Based Dual Antiplatelet Therapy in Coronary Artery Bypass Grafting: A Randomized Clinical Trial on Graft Patency","Inclusion Criteria:\n\n1. Patients 18-80 of age.\n2. Patients undergo planned CABG for the first time with ≥1 SVGs\n3. Patients with written informed consent.\n\nExclusion Criteria:\n\n1. Patients undergoing concomitant valve surgery (excluding aortic bioprosthesis), aortic surgery, or rhythm surgery during the same session.\n2. Patients undergoing emergency CABG.\n3. Patients with single-vessel coronary artery disease.\n4. Patients with cardiogenic shock or hemodynamic instability.\n5. Patients with sick sinus syndrome, second- or third-degree atrioventricular block.\n6. Patients with contraindications for coronary computed tomography angiography (CCTA) or coronary angiography, including contrast media allergy.\n7. Patients requiring antiplatelet therapy other than aspirin or ticagrelor (e.g., clopidogrel, prasugrel) and unable to discontinue such medication after CABG, based on physician or investigator judgment.\n8. Patients on oral anticoagulants before CABG who must continue anticoagulation therapy postoperatively.\n9. Patients with contraindications for ticagrelor or aspirin, including:\n\n   9.1Bleeding diathesis within the past 3 months. 9.2Severe gastrointestinal bleeding within the past year. 9.3Peptic ulcer (even without bleeding) within the past 3 years. 9.4History of intracranial hemorrhage, aspirin allergy, or severe aspirin-induced gastrointestinal reaction.\n10. Patients with a drug-eluting stent (DES) in a coronary or cerebral artery within 6 months before CABG, or a bare-metal stent (BMS) within 1 month before CABG.\n11. Patients with thrombocytopenia (\\\u003C100 x 10⁹\u002FL) before CABG.\n12. Patients with severe renal dysfunction requiring dialysis or active liver disease, including unexplained persistent transaminase elevation or transaminase levels \\>3× the upper normal limit.\n13. Patients using strong CYP3A4 inhibitors.\n14. Patients requiring methotrexate and ibuprofen therapy.\n15. Patients with active malignant tumors with an increased risk of bleeding, as determined by the investigator.\n16. Pregnant or breastfeeding women, and those who have given birth within the past 90 days.\n17. Premenopausal women not using adequate contraception. Adequate contraception requires at least two reliable methods, including one barrier method.",true,"18 Years","80 Years",{"count":51,"type":19},300,[53],"NA","This randomized controlled trial aims to evaluate the impact of different durations of Ticagrelor-based dual antiplatelet therapy (DAPT) on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting (CABG). A total of 300 patients will be randomly assigned to receive Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, 6 months, or 12 months, followed by aspirin monotherapy.The primary outcome is 1-year graft patency, assessed via coronary CT angiography. Secondary outcomes include bleeding events (BARC classification), major adverse cardiovascular and cerebrovascular events (MACCE), and all-cause mortality. The study aims to determine the optimal DAPT duration to balance graft patency benefits and bleeding risks, ultimately guiding postoperative antiplatelet strategies for CABG patients.",[56,57,58,26],"Coronary Artery Disease","Coronary Artery Bypass Grafting","Saphenous Vein","NOT_YET_RECRUITING","2026-04-21",{"date":62,"type":31},"2026-04-24",{"date":64,"type":19},"2026-05-01",{"date":66,"type":19},"2027-03-20",{"name":68,"class":38},"Kexiang Liu, MD",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":80,"briefSummary":81,"conditions":82,"keywords":106,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":69},"100557242","single-vs-dual-antiplatelet-therapy-in-elderly-or-hbr-patients-undergoing-percutaneous-intervention-with-dcb-piccoleto-iv-epic-38-100557242","NCT06535568","Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","International, Multicenter, Investigator-driven Randomized Clinical Trial to Assess the Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (PICCOLETO IV-EPIC 38)","PIV-EPIC","Inclusion Criteria:\n\nMale and female patients who meet the following criteria:\n\n* Age ≥ 75 years or age ≥ 18 years at high bleeding risk;\n* Successful PCI with Essential Pro DCB just performed, in 1, 2 or 3 coronary vessels;\n* Stable or unstable coronary syndromes;\n* De novo coronary lesions in vessels with diameter ≥2.0 and ≤4.0 mm (visual estimation);\n* Informed consent to participate in the study given by the patient or impartial witness.\n\nExclusion Criteria:\n\n* Stent implantation during index or recent (\\\u003C6 months) procedure;\n* Known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel or contrast media, or any of their excipient which cannot be adequately pre-medicated;\n* Pregnancy at the time of hospitalization;\n* Patients participating in another clinical study in which an investigational drug or device was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer;\n* ST-elevation myocardial infarction;\n* Life expectancy \\\u003C12 months;\n* Left ventricular ejection fraction \\\u003C30%;\n* Visible thrombus at lesion site;\n* Target lesion\u002Fvessel with any of the following characteristics:\n\n  * severe and\u002For \\>270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory);\n  * left main stem stenosis \\>50%;\n  * target lesion is in the left main stem;\n  * chronic total occlusion with anticipated necessity of retrograde approach;\n  * lesion is in a bypass graft.\n* History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines (NSAIDs);\n* History of gastrointestinal perforation, ulceration, or bleeding (peptic ulcer bleeding-PUBs) related to previous use of NSAIDs or anticoagulant medications, or intracranial hemorrhage;\n* Acute gastrointestinal ulcers;\n* Hemorrhagic diathesis (including known bleeding disorders or ongoing active bleeding);\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin);\n* Severe hepatic impairment (Child-Pugh C), with elevated liver enzymes (ALT\u002FAST \\> 2 x ULN or total bilirubin \\>1.5 x ULN);\n* Severe cardiac failure (NYHA grade III or IV);\n* Combination with methotrexate at doses of 15 mg\u002Fweek or more;\n* Patients with baseline neutrophil counts \\\u003C 1500 cells\u002Fmm³;\n* Breastfeeding women;\n* Full-blown thyrotoxicosis;\n* Patients with a very high risk of thrombosis.",{"count":79,"type":19},576,[53],"This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with the latest generation drug-coated balloon (DCB). The study includes patients with stable or unstable coronary syndromes and aims to assess rates of ischemic and bleeding adverse events.",[83,84,85,86,87,88,89,56,90,91,92,93,94,95,96,97,98,99,100,26,101,102,103,104,105],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Myocardial Ischemia","Atherosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Acute Coronary Syndrome","Coronary Stenosis","Molecular Mechanisms of Pharmacological Action","Enzyme Inhibitors","MTOR Inhibitors","Protein Kinase Inhibitors","Physiological Effects of Drugs","Immunosuppressive Agents","Antineoplastic Agents","High Bleeding Risk","Single Antiplatelet Therapy","Cyclooxygenase Inhibitors","P2Y12 Inhibitor","Platelet Aggregation Inhibitors","Aspirin","Clopidogrel",[107,108,109,110,111,112,113,114,115,116],"DCB","Angioplasty","Paclitaxel","Antiplatelet treatment","Single antiplatelet therapy (SAPT)","Dual antiplatelet therapy (DAPT)","High bleeding risk (HBR)","MACE","Native CAD","stable or unstable coronary syndromes","2026-01-21",{"date":119,"type":31},"2026-01-22",{"date":121,"type":31},"2026-01-10",{"date":123,"type":19},"2028-02-20",{"name":125,"class":38},"Fondazione Ricerca e Innovazione Cardiovascolare ETS",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":136,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":69},"100517170","24-versus-12-month-dual-antiplatelet-therapy-after-drug-eluting-stent-in-patients-with-elevated-lipoproteina-levels-a-prospective-multicenter-double-blind-placebo-controlled-randomized-trial-100517170","NCT06014060","24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial","DAPT-Lp(a)","Inclusion Criteria:\n\n1. Male or nonpregnant female between 18-75 years;\n2. Subjects with Lp(a) levels \\> 30mg\u002FdL before percutaneous coronary intervention (PCI);\n3. PCI procedure with drug-eluting stent (DES) implantation and no cardiovascular events or BARC type 2, 3, or 5 bleeding events occurring within 12 months after the procedure\n4. Subjects (or legal guardian) understand the trial requirements and the treatment procedures and provides written informed;\n\nExclusion Criteria:\n\n1. Subjects with Lp(a) \\\u003C 30mg\u002FdL or Lp(a) level unavailable before PCI;\n2. Subjects who experience adverse cardiovascular events (death, myocardial infarction, stent thrombosis, stroke, repeat coronary revascularization, or Bleeding Academic Research Consortium \\[BARC\\] type 2, 3 or 5 bleeding) within 1-year after PCI;\n3. BARC type 2, 3, or 5 bleeding occurred before PCI\n4. Unable to tolerate DAPT therapy or anticoagulant therapy at the same time, long-term use of non-steroidal anti-inflammatory drugs is required Or glucocorticoids;\n5. Discontinuation of DAPT for ≥14 days for planned surgical procedures in the next 12 months;\n6. Systolic blood pressure \\\u003C 90mmHg for \\> 30 minutes accompanied by hypoperfusion symptoms or systolic blood pressure ≥ 90mmHg is maintained with mechanical\u002Fpharmacologic hemodynamic support;\n7. Persistent symptoms of myocardial ischemia;\n8. Moderate to severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification III or IV) or last known left ventricular ejection fraction (LVEF) \\\u003C 40%;\n9. Severe valvular heart disease, myocarditis or cardiomyopathy;\n10. Severe hepatic insufficiency (ALT or AST \\> 3 times upper limit of normal, total bilirubin \\> 2.5 times upper limit of normal);\n11. Severe renal dysfunction, defined as creatinine clearance \\\u003C30 mL\u002Fmin or estimated glomerular filtration (eGFR) rate less than 30 ml\u002Fmin\u002F1.73m2, or requirement for peritoneal dialysis or hemodialysis for renal insufficiency;\n12. Severe acute or chronic infectious disease;\n13. History of severe rheumatic immune disease or malignant tumor;\n14. Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies), or receiving other investigational agent(s);\n15. Drug or alcohol abuse, and inability\u002Funwillingness to abstain from drug abuse and excessive alcohol consumption during the study;\n16. Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal);\n17. Known significant active and uncontrolled disease, or any medical, physical condition, as judged by the investigator Or surgical status, may interfere with participation in this study\n18. Mental\u002Fpsychological disorder or any other reason that the subject is expected to have difficulty complying with the study requirements or understanding the participants With the objectives and potential risks of the study;\n19. To the knowledge of the investigator, subjects were unlikely to follow up or were not expected to complete 1 year of follow-up;\n20. Life expectancy is less than 1 year;\n\n22\\. Refusal to participate in the study","75 Years",{"count":135,"type":19},3300,[53],"1. Main objective Among patients with elevated Lp(a) levels (\\>30mg\u002FdL) who did not experience cardiovascular events or BARC type 2, 3, or 5 bleeding within 12 months after PCI and DES implantation, was it possible to reduce the primary adverse cardiovascular and cerebrovascular events (a composite endpoint consisting of all-cause death, non-fatal myocardial infarction, and stroke) by extending the duration of DAPT (24 months) compared to the standard duration (12 months)? (Efficacy test)\n2. Secondary Objectives Key secondary research objective: Among patients with elevated Lp(a) levels (\\> 30mg\u002FdL) who underwent PCI and received DES implantation within 12 months after the procedure, and who did not experience cardiovascular events or BARC type 2, 3, or 5 bleeding, whether extending the DAPT duration (24 months) compared to the standard DAPT duration (12 months) does not result in an increase in clinical net adverse events (a composite endpoint consisting of all-cause death, non-fatal myocardial infarction, stroke, and BARC type 3 or 5 bleeding) compared to the standard DAPT duration. (Non-inferiority test) Other secondary research objectives: To evaluate the differences in the incidence of the composite endpoint consisting of BARC type 3 or 5 bleeding (the primary safety endpoint) between extending the DAPT duration (24 months) and the standard DAPT duration (12 months); the differences in the incidence of the composite endpoint consisting of cardiovascular death and myocardial infarction; the differences in the incidence of the composite endpoint consisting of all-cause death and myocardial infarction; the differences in the incidence of stent thrombosis; the differences in the incidence of any myocardial infarction; the differences in the incidence of target vessel myocardial infarction; the differences in the incidence of stroke; the differences in the incidence of ischemic stroke; the differences in the incidence of hemorrhagic stroke; the differences in the incidence of cardiovascular death; the differences in the incidence of all-cause death; the differences in the incidence of repeat revascularization; the differences in the incidence of target vessel revascularization; the differences in the incidence of BARC type 2, 3, or 5 bleeding; the differences in the incidence of any bleeding.",[139,56,140,26],"Elevated Lipoprotein(a) Level","Drug-Eluting Stent",[142,56,140,143,26],"Lipoprotein(a)","Percutaneous Coronary Intervention","2025-07-16",{"date":146,"type":31},"2025-07-18",{"date":148,"type":31},"2025-06-20",{"date":150,"type":19},"2028-12-31",{"name":152,"class":153},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":165,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":69},"100521886","efficacy-and-safety-of-short-duration-of-dapt-after-genoss-des-implantation-in-patients-with-coronary-artery-disease-100521886","NCT06075420","Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease","A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease","DAPTShort","Inclusion Criteria:\n\n1. Patients of 19 and over\n2. Patients with coronary artery disease treated with GENOSS SES\n3. Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants\n\nExclusion Criteria:\n\n1. Patients with cardiogenic shock at the time of hospitalization\n2. Patients who are pregnant or planning to become pregnant\n3. Patients with a life expectancy of less than 1 year\n4. Patients participating in randomized controlled trials using other medical devices\n5. Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)","19 Years",{"count":164,"type":19},1000,"12 Months","OBSERVATIONAL","The objective of study is to evaluate the efficacy and safety of short duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease.",[143,26],"2025-02-18",{"date":171,"type":31},"2025-02-21",{"date":173,"type":31},"2021-08-18",{"date":175,"type":19},"2027-12-31",{"name":177,"class":178},"Genoss Co., Ltd.","INDUSTRY",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":4,"enrollmentInfo":186,"targetDuration":165,"studyType":166,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":69},"100521887","efficacy-and-safety-of-1-year-duration-of-dapt-after-genoss-des-implantation-in-patients-with-coronary-artery-disease-according-to-the-complex-higher-risk-procedure-100521887","NCT06075433","Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure","A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of 1 Year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-Risk Procedure","DAPTLong",{"count":164,"type":19},"The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.",[56,143,26],{"date":171,"type":31},{"date":191,"type":31},"2022-05-13",{"date":175,"type":19},{"name":177,"class":178},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":20,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":69},"100565941","efficacy-and-safety-of-shortening-dual-antiplatelet-therapy-duration-with-ivus-guidance-in-pci-patients-100565941","NCT06648720","Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients","Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients: a Multicenter, Randomized Controlled Trial","SHORTDAPT","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n* Patients with the following clinical indications for PCI:\n\n  * Unstable Angina: Prolonged chest pain at rest, new-onset angina within the past 2 months, or increasing frequency\u002Fseverity of angina attacks.\n  * Acute Myocardial Infarction (MI): With or without ST-elevation.\n  * Chronic Coronary Syndrome: Requiring coronary revascularization.\n* Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n* Neurological Complications: Stroke or any permanent neurological deficits within the last 3 months.\n* Coronary Artery Bypass Graft Surgery: History of CABG surgery.\n* Planned Surgery: Patients who have surgeries planned within the next 12 months.\n* Severe Chronic Kidney Disease: Patients with an estimated glomerular filtration rate (eGFR) of less than 20 ml\u002Fmin\u002F1.73 m² or patients on dialysis.\n* Chronic Anticoagulation Therapy: Patients requiring chronic oral anticoagulation (e.g., warfarin, DOACs) beyond DAPT.\n* Thrombocytopenia: Platelet count less than 100,000\u002Fmm³.\n* Contraindications to Antiplatelet Therapy: Allergy or intolerance to aspirin or P2Y12 inhibitors.\n* Liver Disease: Patients with cirrhosis or significant liver dysfunction.\n* Limited Life Expectancy: Patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n* Other Medical Conditions: Any condition that might interfere with adherence to the study protocol or follow-up schedule.",{"count":203,"type":19},3566,[53],"This study is designed to assess the efficacy and safety of de-escalating dual antiplatelet therapy (DAPT) at 1 month compared to the standard 12 months of therapy in patients undergoing percutaneous coronary intervention (PCI) guided by intravascular ultrasound (IVUS). The main outcomes measured will include major adverse cardiovascular and cerebrovascular events (NACCE), bleeding events, and target vessel failure (TVF). The goal is to evaluate whether a shorter duration of DAPT is non-inferior to the standard 12-month regimen in preventing ischemic events while reducing the incidence of bleeding.",[207,208,209,26],"Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention (PCI)","Intravascular Ultrasound",[211,212,213,207],"Shortening DAPT duration","Intravascular Ultrasound (IVUS)","Percutaenous Coronary Intervention (PCI)","2024-10-16",{"date":216,"type":31},"2024-10-18",{"date":218,"type":19},"2025-03-01",{"date":220,"type":19},"2029-03-01",{"name":222,"class":38},"University Medical Center Ho Chi Minh City (UMC)",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":133,"enrollmentInfo":230,"targetDuration":4,"studyType":20,"phases":232,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":244,"leadSponsor":246,"locationsCount":69},"100542142","early-phase-1-oct-or-angiography-guided-de-escalation-of-dapt-100542142","NCT06339021","OCT or Angiography Guided De-escalation of DAPT","Evaluation of Neointimal Coverage After Guiding De-escalation of Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention by Optical Coherence Tomography or Angiography of STEMI Patients","Inclusion Criteria:\n\n1. 18 \\~ 85 years old adult patients;\n2. Patients diagnosed with STEMI and undergoing PCI.\n3. Patients able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n1. Prior history of intracranial hemorrhage or ischemic stroke during the past 6 months；\n2. Allergy to aspirin or clopidogrel or ticagrelor;\n3. Occurrence of major adverse cardiovascular event (MACE) within 30 days after undergoing PCI;\n4. Platelet count \\\u003C 50 × 109\u002FL;\n5. Major bleeding during the past 12 months;\n6. Any form of oral, long-term anticoagulation therapy;\n7. Pregnancy or lactation;\n8. Suspected aortic dissection;\n9. Coronary CT-negative patients;\n10. Life expectancy \\\u003C1 year;\n11. Uncontrolled hypertension, systolic blood pressure (SBP) ≥180 mmHg, and\u002For diastolic blood pressure (DBP) ≥110 mmHg;\n12. Comorbid conditions included the presence of any of the following: cardiogenic shock, chronic congestive heart failure with NYHA classes III or IV, left ventricular ejection fraction (LVEF) \\\u003C 35% at transthoracic echocardiography, hypotension with SBP \\\u003C 90mmHg and\u002For DBP \\\u003C 60mmHg, severe arrhythmia (including high-degree AV block, sick sinus syndrome, sustained ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, hepatic insufficiency due to non-cardiac causes (ALT or AST more than three times the upper limit of the institution's normal reference ranges), cirrhosis, severe renal failure (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2);\n13. Surgery plan within 30 days;\n14. Psychiatric abnormalities or alcohol dependence;\n15. Patients who are participating in other clinical trials;\n16. Unable to tolerate 1 month of DAPT;\n17. Angiographic triple vessel disease coronary disease;\n18. Other situations judged by the investigators not to be suitable for the clinical trial.",{"count":231,"type":19},80,[233],"EARLY_PHASE1","Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus. In addition, the incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized OCT-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Regarding the antithrombotic therapy after revascularization, the 2023 ESC guidelines recommend the P2Y12 receptor inhibitor de-escalation (i.e. switching from ticagrelor to clopidogrel) in ACS patients may be considered as an alternative strategy to the default treatment regimen in order to reduce the risk of bleeding events.\n\nBased on the above conclusions, we designed a single-center, prospective, randomized controlled, exploratory study trial to evaluate whether the utility of OCT for guiding PCI with DES followed by antiplatelet de-escalation therapy could further reduce the stent-induced intimal hyperplasia of STEMI patients after stent implantation.",[236,26,237,238,239],"Optical Coherence Tomography","Antiplatelet De-escalation","Neointimal Coverage","ST Elevation Myocardial Infarction","2024-03-24",{"date":242,"type":31},"2024-04-01",{"date":242,"type":19},{"date":245,"type":19},"2026-12-01",{"name":247,"class":38},"Shenyang Northern Hospital"]